# Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction

> **NCT02442492** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of British Columbia** · enrollment: 21 (actual)

## Conditions studied

- Intrauterine Growth Restriction (IUGR)
- Fetal Growth Restriction (FGR)

## Interventions

- **DRUG:** Sildenafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02442492
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2018-07
- **Final completion:** 2019-04
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Trial terminated following Dutch DSMB recommendation for their Study
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442492, "Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02442492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*